PEIJIA-B(09996): Jiaqi Biology and Berang Medical have entered into an exclusive distribution agreement.

PEIJIA-B (09996) announced that its subsidiary Shanghai Jiaqi Biological Technology Suzhou Co., Ltd. (Jiaqi Biological) has entered into an exclusive distribution agreement with B. Braun Medical (Shanghai) International Trading Co., Ltd. (B. Braun Medical). According to the agreement, Jiaqi Biological has obtained the exclusive distribution rights of B. Braun Medical's product SeQuent Please CIS Paclitaxel Drug-Coated Balloon Catheter (SeQuent Please CIS) in mainland China. SeQuent Please CIS is a intracranial paclitaxel drug-coated balloon catheter developed based on B. Braun Medical's mature drug-coated balloon (DCB) technology. When mechanically dilating the target lesion, this product will release the drug-coated paclitaxel precisely to the lesion vessel wall. As an anti-proliferative drug, it effectively inhibits intimal hyperplasia and reduces the risk of restenosis in the long term. The product is designed specifically for the thin and tortuous anatomy of intracranial blood vessels, aiming to provide an innovative "no implant" treatment option for intracranial vascular diseases. As of the date of this announcement, the product's registration application has been submitted to the China National Medical Products Administration. B. Braun Medical is a global medical technology company with extensive experience in the DCB field. Since introducing one of the world's first commercially available DCBs in 2008 (which has now become one of the most extensively studied DCBs in the field of cardiology), B. Braun Medical and its platform products have accumulated rich global clinical application experience and robust evidence-based medicine. Collaborating with B. Braun Medical further enriches the group's neurointerventional product portfolio and strengthens the group's strategic layout in the field of innovative intracranial interventional solutions. With Jiaqi Biological's local commercialization resources and academic promotion capabilities, the group expects to accelerate the future clinical applications of SeQuent Please CIS upon obtaining regulatory approval and further consolidate the group's position in the neurovascular intervention market.